0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in Macquarie analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 22:35 ET (03:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。